Identification of Deleterious <i>NOTCH</i> Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC
2020 · Clinical Cancer Research · 136 citations
https://doi.org/10.1158/1078-0432.ccr-19-3976
F
Feifei Gu
Union Hospital(CN)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
55
Papers
516
Citations
12
h-index
15
i10-index
Feifei Gu is an academic researcher from Union Hospital. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & RNA modifications and cancer. The author has an h-index of 12, co-authored 47 publications.
Papers by this author
worksLung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
2016 · Journal of Hematology & Oncology · 42 citations
https://doi.org/10.1186/s13045-016-0296-8
Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation
2020 · Cancer Immunology Immunotherapy · 19 citations
https://doi.org/10.1007/s00262-020-02510-1
A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro
2017 · Journal of Hematology & Oncology · 5 citations
https://doi.org/10.1186/s13045-017-0429-8
Additional file 3 of Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3–4 NSCLC patients
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.19218828
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat